Explore the latest news and updates from our Fibrolamellar community.
Read about a new collaboration with Pangea Biomed, a beautiful account of a mother’s journey caring for her son, and explore key differences between FLC and HCC.
FibroFighters is proud to announce our new partnership with Pangea Biomed.
This adds another critical tool to better insights into clinical care for Fibrolamellar patients while continuing to gather important clinical data.
Check out the press release by following the link below.
FibroFighters Foundation does not underestimate the power of accountability and a public promise. Making these promises to our community is a meaningful way to hold ourselves accountable to reaching foundation goals.
FibroFighters is committed to help every patient and keeping our promises to all who desire our help!
Learn more about the #OurPromise4Fibro campaign below.
Dr. Kent has and continues to be instrumental in providing hope and treatments to well over 100 fibrolamellar patients, including those in the collage to the left.
Since retiring from Rush, FibroFighters was extremely pleased when Paul accepted the position of Consulting Medical Director, bringing his years of experience, devotion, knowledge of FLC, compassion, and desire to collaborate with everyone in the Fibrolamellar universe. Paul is a fighter and not afraid to think out of the box when standing up and advocating for every Fibro patient and family who reaches out.
xCures and FibroFighters began to collaborate 18 months ago by enrolling FLC patients into their xINFORM platform.
Current patients can receive direct benefits while helping the community as a whole learn about current treatments. xCures allows patients to see their entire medical history in one place.
Learn more about the platform and other benefits by clicking the link below.
This unique collaboration is led by our Medical Director, Dr. Paul Kent.
Since launching August 2022, we have discussed dozens of FLC cases in detail among a group of FLC experts and have witnessed a tremendous positive impact on case management.
To our knowledge this is the only FLC-specific tumor board which invites experts and your medical team to review your case and come to a consensus about the direction of your treatment.
By using Dr. Nagourney’s 20-year-old proprietary functional tumor profiling, we may find key sensitives to your specific tumor using customized assays based on current papers and our combined knowledge.
Most importantly, since The Nagourney Cancer Institute is a CLIA-approved lab, our patients, their medical teams, and insurance companies can legally receive and act upon the results, unlike research centers.
Your support can make a difference in the lives of our Fibrolamellar patients and caregivers by supporting our patient directed initiatives.
We support translational projects, pilot research studies, an upcoming clinical trial, and more!
Pictured: A Fighter with his younger brother supporting him in the background. Courtesy of Sharon Elizabeth Photography N.C.